Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela C Doran

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 7, 2024
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Gabrielle M Gualtieri, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2008
3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulatorsLei Zhang, Bruce N Rogers, Allen J Duplantier, et al.
Biopharmaceutics & Drug Disposition|February 24, 2023
Investigating CNS distribution of PF-05212377, a P-glycoprotein substrate, by translation of 5-HT<sub>6</sub> receptor occupancy from non-human primates to humansAarti Sawant-Basak, Laigao Chen, Peter Lockwood, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 14, 2022
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Amanda King-Ahmad, et al.
ACS Chemical Neuroscience|June 14, 2017
Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) InhibitorsTravis T Wager, Paul Galatsis, Ramalakshmi Y Chandrasekaran, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue bindingXingrong Liu, Bill J Smith, Cuiping Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 9, 2006
Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentrationXingrong Liu, Bill J Smith, Cuiping Chen, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2009
3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimizationAllen J Duplantier, Ivan Efremov, John Candler, et al.
Journal of Medicinal Chemistry|March 4, 2011
1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosisLei Zhang, Michael A Brodney, John Candler, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 7, 2024
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Gabrielle M Gualtieri, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2008
3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulatorsLei Zhang, Bruce N Rogers, Allen J Duplantier, et al.
Biopharmaceutics & Drug Disposition|February 24, 2023
Investigating CNS distribution of PF-05212377, a P-glycoprotein substrate, by translation of 5-HT<sub>6</sub> receptor occupancy from non-human primates to humansAarti Sawant-Basak, Laigao Chen, Peter Lockwood, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 14, 2022
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Amanda King-Ahmad, et al.
ACS Chemical Neuroscience|June 14, 2017
Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) InhibitorsTravis T Wager, Paul Galatsis, Ramalakshmi Y Chandrasekaran, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 4, 2005
Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue bindingXingrong Liu, Bill J Smith, Cuiping Chen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 9, 2006
Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentrationXingrong Liu, Bill J Smith, Cuiping Chen, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2009
3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimizationAllen J Duplantier, Ivan Efremov, John Candler, et al.
Journal of Medicinal Chemistry|March 4, 2011
1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosisLei Zhang, Michael A Brodney, John Candler, et al.
Pageof 2